Buchumschlag

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study

MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients’ MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schwalbe, Edward C. (VerfasserIn) , Lindsey, Janet C. (VerfasserIn) , Danilenko, Marina (VerfasserIn) , Hill, Rebecca M. (VerfasserIn) , Crosier, Stephen (VerfasserIn) , Ryan, Sarra (VerfasserIn) , Williamson, Daniel (VerfasserIn) , Castle, Jemma (VerfasserIn) , Hicks, Debbie (VerfasserIn) , Kool, Marcel (VerfasserIn) , Milde, Till (VerfasserIn) , Korshunov, Andrey (VerfasserIn) , Pfister, Stefan (VerfasserIn) , Bailey, Simon (VerfasserIn) , Clifford, Steven C. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 2025
In: Neuro-Oncology
Year: 2025, Jahrgang: 27, Heft: 1, Pages: 222-236
ISSN:1523-5866
DOI:10.1093/neuonc/noae178
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1093/neuonc/noae178
Verlag, kostenfrei, Volltext: https://academic.oup.com/neuro-oncology/article/27/1/222/7815636?login=true
Volltext
Verfasserangaben:Edward C. Schwalbe, Janet C. Lindsey, Marina Danilenko, Rebecca M. Hill, Stephen Crosier, Sarra L. Ryan, Daniel Williamson, Jemma Castle, Debbie Hicks, Marcel Kool, Till Milde, Andrey Korshunov, Stefan M. Pfister, Simon Bailey, Steven C. Clifford
Beschreibung
Zusammenfassung:MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients’ MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management.We characterized the clinical and molecular correlates of MYC- (MYC-MB; n = 64) and MYCN-amplified MBs (MYCN-MB; n = 95), drawn from >1600 diagnostic cases.Most MYC-MBs were molecular group 3 (46/58; 79% assessable) and aged ≥3 years at diagnosis (44/64 [69%]). We identified a “canonical” very high-risk (VHR) MYC-amplified group (n = 51/62; 82%) with dismal survival irrespective of treatment (11% 5-year progression-free survival [PFS]), defined by co-occurrence with ≥1 additional established risk factor(s) (subtotal surgical-resection [STR], metastatic disease, LCA pathology), and commonly group 3/4 subgroup 2 with a high proportion of amplified cells. The majority of remaining noncanonical MYC-MBs survived (i.e. non-group 3/group 3 without other risk features; 11/62 (18%); 61% 5-year PFS). MYCN survival was primarily related to molecular group; MYCN-amplified SHH MB, and group 3/4 MB with additional risk factors, respectively defined VHR and HR groups (VHR, 39% [35/89]; 20% 5-year PFS/HR, 33% [29/89]; 46% 5-year PFS). Twenty-two out of 35 assessable MYCN-amplified SHH tumors harbored TP53 mutations; 9/12 (75%) with data were germline. MYCN-amplified group 3/4 MB with no other risk factors (28%; 25/89) had 70% 5-year PFS.MYC(N)-amplified MB displays significant clinicobiological heterogeneity. Diagnostics incorporating molecular groups, subgroups, and clinical factors enable their risk assessment. VHR “canonical” MYC tumors are essentially incurable and SHH-MYCN-amplified MBs fare extremely poorly (20% survival at 5 years); both require urgent development of alternative treatment strategies. Conventional risk-adapted therapies are appropriate for more responsive groups, such as noncanonical MYC and non-SHH-MYCN MB.
Beschreibung:Online verfügbar: 08. Oktober 2024
Gesehen am 16.04.2025
Beschreibung:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noae178

Ähnliche Einträge